Cell membrane cation transport systems during aldosterone antagonism

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 4, 1996, Pages 462-468

  Lijnen, P ^a,b   Petrov, V ^a  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Blood pressure; Cation transport systems; Erythrocytes; Platelets; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; CALCIUM ION; POTASSIUM ION; SODIUM ION; SPIRONOLACTONE;

ADULT; ARTICLE; BLOOD PRESSURE; CALCIUM TRANSPORT; CATION TRANSPORT; CELL MEMBRANE TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHROCYTE MEMBRANE; HORMONE INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; SODIUM TRANSPORT; THROMBOCYTE MEMBRANE;

ADULT; ALDOSTERONE ANTAGONISTS; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; BLOOD PRESSURE; BODY WEIGHT; ERYTHROCYTES; HEART RATE; HUMANS; MAGNESIUM; MALE; POTASSIUM; SODIUM; SPIRONOLACTONE;

EID: 0029919167     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199604000-00002     Document Type: Article

References (44)

1. Wehling M, Christ M, Gerzer R. Aldosterone-specific membrane receptors and related rapid, non-genomic effects. TIPS 1993;14:1-3.
2. Krozowski Z, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone binding species have identical steroid specificity. Proc Natl Acad Sci USA 1983; 80:6056-60.
3. Quirk SG, Gannell JE, Funder JW. Aldosterone binding sites in pregnant and lactating mammary gland. Endocrinology 1983;113:1812-7.
4. Meyer JW, Nicols NR. Mineralocorticoid binding in cultured smooth muscle cells and in fibroblasts from rat aorta. J Steroid Biochem 1981;14:1157-68.
5. Wehling M, Christ M, Theisen K. High affinity aldosterone binding to plasma membrane rich fractions from mononuclear leukocytes: is there a membrane receptor for mineralocorticoids? Biochem Biophys Res Commun 1991;181:1306-12.
6. Vander AJ, Malvin RL, Wilde WS, Lapides J, Sullivan LP, McMurray VM. Effects of adrenalectomy and aldosterone on proximal and distal tubular sodium reabsorption. Proc Soc Exp Biol Med 1958;99:323-5.
7. Bohr DF, Harris AL, Guthe CC, Webb RC. Hypertension: multiple membrane malfunctions. In: Villareal H, Sambhi MP, eds. Topics in pathophysiology of hypertension. Amsterdam: Martinus Nijhoff, 1984:101-11.
8. Myers JH, Bohr DF. Mechanisms responsible for the pressure elevation in sodium dependent mineralocorticoid hypertension. In: Mantero F, Biglieri EG, Edwards CRW, eds. Endocrinology of hypertension. New York: Raven Press, 1985:131-48.
9. Wehling M, Armanini D, Strasser T, Weber PC. Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes. Am J Physiol 1987;252: E505-8.
10. Christ M, Douwes K, Eisen C, Bechtner G, Theisen K, Wehling M. Rapid effects of aldosterone on sodium transport in vascular smooth muscle. Hypertension 1995;25:117-23.
11. +-pump in human red blood cells. Naunyn Schmiedebergs Arch Pharmacol 1985;329:311-5.
12. Finotti P, Palatini P. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium activated adenosine triphosphatase J Pharmacol Exp Ther 1981;217:784-90.
13. Niutty E, Cusi D, Colombo R, et al. Antihypertensive effect of captopril, canrenoate potassium and atenolol. Relations with red blood cell sodium transport and renin. Am J Hypertens 1988;1:364-71.
14. Samplicini A, Buzzaccarini F, Ceolotto G, et al. Effects of canrenoate on red cell sodium transport and calf flow in essential hypertension. Am J Hypertens 1993;6:295-301.
15. +-cotransport activity in erythrocytes of normal male subjects studied at two occasions. Methods Find Exp Clin Pharmacol 1986;8: 525-33.
16. McCoy EE, Segal DJ, Bayer SM, Strynadka KD. Decreased ATPase and increased sodium content of platelets in Down's syndrome. N Engl J Med 1974;291:950-3.
17. + fluxes by diuretic drugs in human red cells. Biochem Pharmacol 1984;33:2013-20.
18. 3H-ouabain binding by human platelets: evidence for β-adrenergic stimulation of Na,K-ATPase activity. Metabolism 1989;38:773-6.
19. Fyhrquist F, Puutula L. Faster radioimmunoassay of angiotensin I at 37°C. Clin Chem 1978;24:115-8.
20. Lijnen P, Amery A, Fagard R, Corvol P. Direct radioimmunoassay of plasma aldosterone in normal subjects. Clin Chim Acta 1978;84:305-14.
21. Malvano R, Orlandini S, Cozzani P, Duranti P, Simonini N, Salvetta A. Methodological simplification in radioimmunoassay of urinary aldosterone. Clin Chim Acta 1976;139:321-33.
22. Overlack A, Stumpe KO, Ressel C, Kolloch W, Zywzok W, Kruck F. Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension. Klin Wochenschr 1980;58:37-42.
23. + antiport, protein kinase C trio in essential hypertension. Am J Hypertens 1994;7:205-12.
24. 2+ regulation. Eur J Clin Invest 1994;24:525-8.
25. Okada K, Ishikawa S, Saito T. Potentiation by aldosterone of vasopressin-induced calcium kinetics in vascular smooth muscle cells. Clin Exp Pharmacol Physiol 1991;18:643-8.
26. Mironneau J. Calcium channel antogonist effects of spironolactone, an aldosterone antagonist. Am J Cardiol 1990;65: 7K-8K.
27. Dacquet C, Loirand G, Mironneau C, Mironneau J, Pacaud P. Spironolactone inhibition of concentration and calcium channels in portal vein. Br J Pharmacol 1987;92:535-44.
28. Dacquet C, Mironneau C, Mironneau J. Effects of calcium entry blockers on calcium-dependent contractions of rat portal vein. Br J Pharmacol 1987;92:203-12.
29. Mironneau J, Savineau JP, Mironneau C. Effect of indapamide on the electromechanical properties of rat myometrium and rat portal vein. J Pharmacol Exp Ther 1986;236:519-25.
30. Mironneau J, Lalanne C, Mironneau C, Sarineau JP, Lavie JL. Comparison of pimaverium bromide, manganese chloride and D600 effects on electrical and mechanical activities in rat uterine smooth muscle. Eur J Pharmacol 1984;98:99-107.
31. Tepel M, Husseini S, Zidek W. Effect of spironolactone on cytosolic free sodium concentration in platelets from hypertensive patients with primary aldosteronism. Eur J Clin Pharmacol 1993;44(suppl 1):51-2.
32. Constantopoulos G, Gutkowska J, Genest J. The effect of spironolactone on the arterial water, cation and norepinephrine contents of control and one-kidney-one-clip hypertensive dogs. Can J Physiol Pharmacol 1979;57:631-6.
33. 22Na-efflux from arterial smooth muscle. Hypertension 1984;6:425-30.
34. +-pump in human red blood cells. Naunyn Schmiedebergs Arch Pharmacol 1985;329:311-5.
35. Finotti P, Palatini P. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium activated adenosine triphosphatase. J Pharmacol Exp Ther 1981;217:784-90.
36. de Mendonca M, Grichois ML, Pernollet MG, et al. Antihypertensive effect of canrenone in a model where endogenous ouabain-like factors are present. J Cardiovasc Pharmacol 1988;11:75-83.
37. Marcheti G, Vitolo E, DiFrancesco GF, Cavallaro B, Sponzilli C. Positive inotropic effect of K-canrenoate: an investigation in anaesthetized dogs untreated or treated with digitalis. Arch Int Pharmacodyn Ther 1983;266:250-63.
38. Yeh BK, Chiang BN, Sung PK. Antiarrhythmic activity of K-canrenoate in man. Am Heart J 1976;92:308-14.
39. Finotti P, Antonello A. Canrenoate reversal of inhibitory effects of digoxin on basal and furosemide-stimulated renin secretion. Clin Pharmacol Ther 1982;32:1-6.
40. Mugge A, Schmitz W, Scholzz H. Negative inotropic effects of aldosterone antagonists in isolated human and guinea pig ventricular heart muscle. Klin Wochenschr 1984;62:717-23.
41. + Transport in primary hypertension. Ann NY Acad Sci 1986;488:187-95.
42. de Mendonca M, Grichois ML, Pernollet MG, et al. Hypotensive action of canrenone in a model of hypertension where a ouabain-like factor is present. J Hypertens 1985;3 (suppl 3):573-5.
43. Wehling M, Christ M, Gerzer R. Aldosterone-specific membrane receptors and related rapid, non-genomic effects. TIPS 1993;14:1-4.
44. Wehling M, Käsmayr J, Teisen K. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic and non-genomic pathway? Am J Physiol 1991;260:E719-26.